SCHEMBL5831380

SCHEMBL5831380

CCN(CC)C(=O)Cc1nsc(NS(=O)(=O)c2c(C)cc(Cl)cc2Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.43
HSD17B1 P14061 1/20 0.43
HSD17B2 P37059 1/20 0.43
CRHR1 P34998 3/20 0.39
TSPO P30536 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 6/20 0.36
MEN1 O00255 5/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 4/20 0.35
LMNA P02545 2/20 0.35
PFKFB3 Q16875 1/20 0.35
KDM4E B2RXH2 3/20 0.35
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HTT P42858 1/20 0.35
CA1 P00915 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6929888 0.99 HSD11B1 (0.43) HSD11B1HSD17B1HSD17B2CRHR1TSPO
SCHEMBL5830977 0.94 HSD11B1 (0.44) HSD11B1HSD17B1HSD17B2CRHR1TSPO
SCHEMBL5831130 0.91 HSD11B1 (0.37) HSD11B1HSD17B1HSD17B2CRHR1NPC1
SCHEMBL5830489 0.88 HSD11B1 (0.38) HSD11B1NPC1RAB9AKMT2AMEN1
SCHEMBL5831702 0.84 HSD11B1 (0.41) HSD11B1HSD17B1HSD17B2CRHR1NPC1
SCHEMBL3621399 0.83 HSD11B1 (0.64) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL5831400 0.82 KMT2A (0.42) HSD11B1HSD17B1HSD17B2CRHR1KMT2A
SCHEMBL5830785 0.81 HSD11B1 (0.42) HSD11B1NPC1RAB9AKMT2AMEN1
SCHEMBL3248368 0.81 HSD11B1 (0.41) HSD11B1HSD17B1HSD17B2CRHR1TSPO
SCHEMBL6929895 0.80 CRHR1 (0.37) HSD11B1HSD17B1HSD17B2CRHR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 HSD11B1 2/4885HSD17B1 5/4885HSD17B2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.